TKNO (Alpha Teknova Inc) Gross Profit Margin

TKNO (Alpha Teknova) - company brandmark

Alpha Teknova, Inc. (TKNO) creates unique environments in collaboration with gene therapy developers, advancing a pragmatic R&D pipeline of custom reagents. The supply of critical vaccine buffers ensures a stable cash flow and high profitability. The gross margin trend on the GURU.Markets chart clearly demonstrates cost efficiency, where 33.90 characterizes this specific parameter for assessing current solvency.

TKNO - Teknova Inc Return on Gross Profit over the range 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Teknova Inc (TKNO)

- price and consensus price forecast:
- business market valuation indicators:
Basic company analysis:Alpha Teknova, TKNO
Mass-produced product of Alpha Teknova Inc

Gross margin measures the profit share after deducting direct production costs, reflecting the efficiency of cost management for Alpha Teknova, Inc. (TKNO) chemical reagents. By analyzing the gross profit ratio, an investor assesses the company's ability to pass costs onto consumers, which, combined with recurring biopharmaceutical demand, confirms the issuer's exceptional financial stability and cash flow predictability.